Spersadex Comp. 1+5 mg/ml øjendråber, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

spersadex comp. 1+5 mg/ml øjendråber, opløsning

laboratoires thea s.a.s. - chloramphenicol, dexamethasonnatriumphosphat - øjendråber, opløsning - 1+5 mg/ml

Spersadex Comp. 1+5 mg/ml ?jendr?ber, opl?sning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

spersadex comp. 1+5 mg/ml ?jendr?ber, opl?sning

orifarm a/s - chloramphenicol, dexamethasonnatriumphosphat - øjendråber, opløsning - 1+5 mg/ml

Spersadex Comp. 1+5 mg/ml øjendråber, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

spersadex comp. 1+5 mg/ml øjendråber, opløsning

2care4 aps - chloramphenicol, dexamethasonnatriumphosphat - øjendråber, opløsning - 1+5 mg/ml

Spersadex Comp. 1+5 mg/ml øjendråber, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

spersadex comp. 1+5 mg/ml øjendråber, opløsning

paranova danmark a/s - chloramphenicol, dexamethasonnatriumphosphat - øjendråber, opløsning - 1+5 mg/ml

Nexpovio Den Europæiske Union - dansk - EMA (European Medicines Agency)

nexpovio

stemline therapeutics b.v. - selinexor - multipelt myelom - antineoplastiske midler - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Sarclisa Den Europæiske Union - dansk - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - multipelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Oratoria 1 mg/ml øjendråber, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

oratoria 1 mg/ml øjendråber, opløsning

pharmathen s.a. - dexamethasonnatriumphosphat - øjendråber, opløsning - 1 mg/ml

Dexrapid Vet. 2 mg/ml injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

dexrapid vet. 2 mg/ml injektionsvæske, opløsning

richter pharma ag - dexamethasonnatriumphosphat - injektionsvæske, opløsning - 2 mg/ml

Dexafree 1 mg/ml øjendråber, opløsning, enkeltdosisbeholder Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

dexafree 1 mg/ml øjendråber, opløsning, enkeltdosisbeholder

paranova danmark a/s - dexamethasonnatriumphosphat - øjendråber, opløsning, enkeltdosisbeholder - 1 mg/ml

Zeqmelit 6 mg smeltefilm Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

zeqmelit 6 mg smeltefilm

acucort ab - dexamethason - smeltefilm - 6 mg